• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Inotek Pharmaceuticals

edit

Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020.

Milestones

edit

• 
  Inotek Pharmaceuticals added James G. Ham as CFO.
  Posted 6/13/10 at 7:56pm
• 
  Inotek Pharmaceuticals added Paul G. Howes as President and CEO.
  Posted 6/13/10 at 7:56pm
• 
  Inotek Pharmaceuticals received $18M in Series D funding. (6/11/10)
  Posted 6/13/10 at 7:56pm via fiercebiotech.com

Videos

Screenshots

edit

Sources

1. Inotek gathers $18M as it plots PhII trials Read more: Inotek gathers $18M as it plots PhII trials (fiercebiotech.com) [edit]